|
WO2020167912A1
|
|
Anti-peripheral lymph node addressin antibodies and uses thereof
|
|
WO2020163785A1
|
|
Methods and compositions for treating sleep apnea
|
|
WO2020163512A1
|
|
Polysaccharide compositions for use in treating filariasis
|
|
US2018174490A1
|
|
Methods and systems for generating fluid simulation models
|
|
WO2017223457A1
|
|
Generation of brown adipose tissue from pluripotent stem cells in vitro
|
|
WO2017173453A1
|
|
Stimuli-responsive nanoparticles for biomedical applications
|
|
WO2017165661A1
|
|
Signal processing for precise identification and separation of artifact and a signal of interest in a longitudinal signal
|
|
WO2017151912A1
|
|
A reporter platform for real time monitoring of drug efficacy
|
|
WO2017123991A1
|
|
Pyridazine derivatives as eaat2 activators
|
|
WO2017123497A1
|
|
Systems and methods to facilitate delivery of a therapeutic agent into the skin of a subject
|
|
WO2017087708A1
|
|
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
WO2017083809A1
|
|
Targeting oxazole structures for therapy against inflammatory diseases
|
|
WO2017079473A1
|
|
Imaging probe for angiogenic activity in pulmonary arterial hypertension
|
|
US2017121318A1
|
|
Use of small molecule inhibitors to klf10 for modulation of t regulatory cells and cancer immunotherapy
|
|
WO2017069958A2
|
|
Modulation of novel immune checkpoint targets
|
|
WO2017062429A1
|
|
Multicomponent and multifunctional living fiber
|
|
WO2017040960A1
|
|
Programmed cell death 1 (pd-1 ) inhibitor therapy for patients with pd-1 -expressing cancers
|
|
WO2017069822A2
|
|
Shear-thinning compositions as an intravascular embolic agent
|
|
WO2017015271A1
|
|
Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections
|
|
WO2016209943A1
|
|
Home evaluation of the quality of semen samples
|
